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Abstract 
 
Background:  The clinical and functional significance of RNA interefence (RNAi) 
machinery, Dicer and Drosha, in ovarian cancer is not known and was examined. 
 
Methods: Dicer and Drosha expression was measured in ovarian cancer cell lines 
(n=8) and invasive epithelial ovarian cancer specimens (n=111) and correlated with 
clinical outcome. Validation was performed with previously published cohorts of ovarian, 
breast, and lung cancer patients.  Anti-Galectin-3 siRNA and shRNA transfections were 
used for in vitro functional studies.   
 
Results:  Dicer and Drosha mRNA and protein levels were decreased in 37% to 63% of 
ovarian cancer cell lines and in 60% and 51% of human ovarian cancer specimens, 
respectively. Low Dicer was significantly associated with advanced tumor stage 
(p=0.007), and low Drosha with suboptimal surgical cytoreduction (p=0.02). Tumors with 
both high Dicer and Drosha were associated with increased median patient survival 
(>11 years vs. 2.66 years for other groups; p<0.001).  In multivariate analysis, high 
Dicer (HR=0.48; p=0.02), high-grade histology (HR=2.46; p=0.03), and poor 
chemoresponse (HR=3.95; p<0.001) were identified as independent predictors of 
disease-specific survival.  Findings of poor clinical outcome with low Dicer expression 
were validated in separate cohorts of cancer patients.  Galectin-3 silencing with siRNA 
transfection was superior to shRNA in cell lines with low Dicer (78-95% vs. 4-8% 
compared to non-targeting sequences), and similar in cell lines with high Dicer.   
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Conclusions:  Our findings demonstrate the clinical and functional impact of RNAi 
machinery alterations in ovarian carcinoma and support the use of siRNA constructs 
that do not require endogenous Dicer and Drosha for therapeutic applications. 
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Introduction 
Since the discovery that gene expression can be altered by interfering RNA molecules 
(RNAi)1, abundant research has focused on the role of RNAi in human cancer 
pathogenesis.  Targeting specific genes allows investigators to dissect and identify key 
regulators of angiogenic, proliferative, and survival pathways.  In addition, RNAi 
applications have been tested as potential therapeutic modalities in preclinical cancer 
studies2, 3 and may silence specific genes that are not inhibited by current therapeutic 
agents. 
 
Regulation of gene expression by RNAi occurs through either the micro-interfering 
(miRNA) or small-interfering (siRNA) pathway.  In the nucleus, endogenous RNA 
segments are processed by the ribonuclease III enzyme Drosha into precursor short 
hairpin RNA structures (approx 60-70 nt)4, 5, then translocated to the cytoplasm and 
processed by Dicer, also an RNA endonuclease, resulting in mature (19-21 nt) double-
stranded RNA fragments6.  Translational repression or degradation of host mRNA 
occurs following binding of miRNA with the RNA-induced silencing complex, RISC7, 8.  
The production of siRNA molecules occurs in a similar manner, although Drosha 
processing is not required9.   
 
Since, components of the RNAi cascade directly affect the processing and maturation of 
miRNAs5, we asked whether altered expression of RNAi machinery, Dicer and Drosha, 
could impact the clinical outcome of patients with ovarian cancer.  To address this 
question, we correlated Dicer and Drosha expression in ovarian cancers with clinical 
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and pathological outcome variables.  Furthermore, the functional relevance of altered 
Dicer expression was examined in vitro.  These findings may not only invoke insight into 
the association of miRNA expression in human cancers, but also support development 
of novel RNAi therapeutic modalities.   
 
Methods and Materials 
Cell lines and culture.  The derivation, sources, maintenance of the ovarian cancer cell 
lines used in this study, HeyA8, SKOV3ip1, A2780-Par, IGROV, EG, 222, OVCAR3, 
and OVCAR420 have been reported previously 10.  The non-transformed ovarian 
surface epithelial cell line HIO-180 was a kind gift from Dr. Andrew Godwin at Fox 
Chase Cancer Center, Philadelphia, PA. 
 
Human samples.  Invasive epithelial ovarian cancer specimens (n=111) were obtained 
for Dicer and Drosha expression analysis from the M. D. Anderson Cancer Center and 
the Brigham and Women’s Gynecologic Oncology Tumor Banks following IRB approval.  
Benign ovarian epithelial samples (n=11) were obtained from microdissected paraffin-
embedded specimens or epithelial scrapings taken following surgical removal.  Clinical 
outcome data were obtained from patient records. Response to initial chemotherapy 
(sensitive, normalization of CA-125 and/or negative second-look laparotomy with no 
recurrence within 6 months of completion of initial chemotherapy; refractory/resistant, 
progression or recurrence within 6 months completing initial chemotherapy) was 
recorded. 
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Gene expression profiling of human cancer specimens with microarrays. The 
relationship between Dicer (212888_at) and Drosha (218269_at) expression and patient 
survival in ovarian (GEO accession GSE3149)11, breast (Array Express accession E-
TABM-15812, GEO accession GSE145613, GEO accession GSE 492214), and lung 
(GEO accession GSE3141)11 cohorts was examined using genome-wide gene 
expression profiling with either Affymetrix HG U133A or Affymetrix HG U133 Plus 2.0 
arrays. 
 
SiRNA and shRNA transfection.  Anti-Galectin-3 (target sequence: 
GTACAATCATCGGGTTAAATT; Dharmacon, Lafayette, CA) and control non-targeting 
(NT) oligonucleotides (target sequence: UUCUCC GAACGUGUCACGU; Qiagen, 
Valencia, CA) were used for siRNA and shRNA transfections.  ShRNA was prepared 
using a lentiviral gene transfer vector (containing green fluorescent protein), as 
previously described15.  For siRNA and shRNA transfections, 2 x 105 cells/well were 
plated and 5 μg of Galectin-3 or NT siRNA was added per manufacturer’s 
protocol.Transfection was considered optimal if >90% transfection rate was achieved.   
 
Western blot analysis.  After protein loading, bands were separated by SDS-PAGE and 
transferred to nitrocellulose paper. Immunoblotting was performed as previously 
described16 using either mouse anti-Dicer (1:1000; Abcam, Cambridge, MA), mouse 
anti-Drosha (1:500; Abcam), or rabbit anti-Galectin-3 antibodies (provided by Dr. 
Avraham Raz, Karmanos Cancer Center, Wayne State University, Detroit, MI). 
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Quantitative real-time PCR analysis.  RNA was extracted and quantitative analysis of 
Dicer and Drosha mRNA expression was performed using the TaqMan gene expression 
assay kit (Applied Biosystems, Foster City, CA) with either Dicer, Drosha, or 18s RNA  
primers (Applied Biosystems) as previously described17, 18.  The final expression values 
represented ratios of either decreased (0 to 1) or increased (>1) expression relative to 
normal ovarian epithelium. 
 
Mutational analysis.  Genomic DNA was sequenced for DICER1 (NM_177438) and 
RNASEN (NM_013235) coding exons and their flanking splice sites to assess for 
potential mutations, as previously described.(REF)    All sequence variants identified 
were verified by manual inspection of the chromatograms by two individuals. 
 
Statistics.  To determine the distribution of Dicer and Drosha levels around cutpoints, 
histograms were created using log2 of the expression ratio and tested for normality with 
the Kolmogorov-Smirnov test.  The Kruskall-Wallis test was used to compare means of 
a continuous variable not conforming to the assumptions of normality.  Contingency 
tables and Fisher’s exact test were used to statistically evaluate the relationship 
between death and categorical variables.  Kaplan-Meier plots were constructed and a 
log-rank test was used to determine differences in survival curves.  Multivariate 
analyses with a Cox proportional hazard model were used to examine the effects of 
Dicer and Drosha expression on death from disease while adjusting for other 
covariates.   
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The relationship between Dicer and Drosha expression and survival in microarray data 
sets was explored for each gene by dichotomizing the cases from each cohort into high 
and low expression groups using the median expression level of that cohort.  The 
significance of the Cox hazard ratio was assessed using Wald’s test (using the package 
“survival” (v 2.34) in the R language for statistical computing (v 2.6.1))19. A p value of 
<0.05 was considered statistically significant for all analyses.  A Bonferroni correction 
was used in analyses involving multiple comparisons.  
 
Results 
Dicer and Drosha expression in ovarian cell lines. Compared to the non-transformed 
ovarian surface epithelial cells, HIO-180, Dicer and Drosha mRNA expression was 
increased by 2.01 to 3.41 fold and 1.08 to 1.87 fold, respectively, in half of the ovarian 
cancer cell lines (Figure 1A).  In the other 4 cell lines, mRNA expression of Dicer (2.0 to 
12.5 fold) and Drosha (1.1 to 15.3 fold) was decreased.Protein expression was 
decreased in 5 of 8 cell lines (1.20 to 5.33 fold) for Dicer, and in 3 of 8, for Drosha (1.09 
to 2.23 fold; Figures 1B and C).  
 
Dicer and Drosha expression in human ovarian cancer tumors. Based on these 
differences, we next examined the expression of Dicer and Drosha in 111 human 
ovarian cancers relative to 11 benign epithelial ovarian specimens by real-time PCR.  
The distribution of Dicer levels in ovarian cancer specimens was bimodal (p<0.01; 
Kolmogorov-Smirnov test for normality) with two ratio peaks (0.43 and 4.25).  The 
division between these two populations corresponded to a Dicer expression ratio of 1.2.  
 9
Drosha levels in cancer specimens followed a normal distribution (p=0.15) with a peak 
corresponding to a median value of 1.  These findings supported our decision to 
dichotomize Dicer and Drosha levels at 1 for further analyses.  Similar to the ovarian 
cell line analysis, expression varied among cancer specimens, with 59.5% and 51.4% 
demonstrating decreased expression of Dicer and Drosha, respectively (Supplementary 
Table 1).  Furthermore, 38.7% of specimens expressed decreased levels of both Dicer 
and Drosha.  Relative to benign ovarian epithelium, the median ratio of expression for 
cancer specimens with decreased Dicer and Drosha was 0.27 (range, 0.01-1.00; three 
specimens with undetectable levels) and 0.52 (range, 0.02-1.00; one specimen 
undetectable), respectively.  Specimens with increased expression demonstrated a 
median Dicer ratio of 3.38 (range, 1.13-10.41) and 1.98 (range, 1.02-18.85) for Drosha.   
 
Dicer and Drosha expression correlate with clinical/pathological features and mortality. 
The demographic characteristics of all patients (mean age 62.5 years) with invasive 
epithelial ovarian carcinoma are listed in Table 1.  Among all ovarian cancer patients, 
most had advanced stage and poorly differentiated tumors, and 77% had undergone 
optimal primary tumor reductive surgery (residual tumor ≤ 1 cm).  The majority of 
patients (53.2%) had tumors that were sensitive to initial chemotherapy compared to 
33.3% with either refractory or resistant disease (data missing for 13.5%).  In separate 
univariate analyses, neither Dicer nor Drosha levels were associated with age, grade, or 
chemotherapy response (Table 2).  However, low Dicer significantly correlated with 
advanced stage (p<0.01), and low Drosha with greater likelihood of suboptimal 
cytoreductive surgery (p=0.02). In light of these findings, we next evaluated whether 
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Dicer and/or Drosha were related to patient mortality (Figure 2A and B).  Median overall 
survival was substantially associated with both low tumor Dicer expression (2.33 vs. 
9.25 years; p<0.001) and low Drosha expression (2.74 vs. 7.92 years; p=0.008).  
Compared to other groups, tumors with both high Dicer and Drosha expression were 
associated with increased median patient survival time (>11 years [median survival not 
reached] vs. 2.66 years; p<0.001).  In univariate analyses, death from disease was 
associated with both low Dicer and low Drosha expression (p=0.01 and p=0.007, 
respectively).  In multivariate analysis (variables in this model included age, stage, 
grade, Dicer, Drosha, cytoreduction, and response to initial chemotherapy), poorly 
differentiated tumors (p=0.03) and resistant/refractory chemoresponse (p<0.001) were 
predictors of poor survival.  Furthermore, increased Dicer expression demonstrated a 
protective effect in ovarian cancer patients (HR, 0.48; 95% CI, 0.26-0.87; p=0.02).  
Next, we determined whether increased expression of Dicer and Drosha demonstrated 
a greater protective effect when paired in an interaction model. Interestingly, increased 
Dicer and Drosha demonstrated a greater effect toward improved survival (HR, 0.25; 
95% CI, 0.11-0.55; p<0.001) than the effects of each gene alone. 
 
To validate our findings, we correlated expression of Dicer and Drosha with patient 
survival in a previously reported cohort of 132 ovarian cancer patients11.  Similar to our 
findings, high expression of Drosha (HR, 0.55; 95% CI, 0.34-0.89; p=0.014) or Dicer 
(HR, 0.53; 95% CI, 0.33-0.85; p=0.008) was associated with increased survival (Figure 
2C). 
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To examine how robust this association might be across other tumors, we measured 
Dicer and Drosha relative expression ratios in two separate cohorts of 91 lung cancer11 
and 129 breast cancer patients12.  High expression of Dicer (HR, 0.43; 95% CI, 0.23-
0.80; p=0.008), but not of Drosha (HR, 1.34; 95% CI, 0.74-2.40; p=0.33), was 
associated with increased survival in the lung-cancer cohort (Figure 2D).  Similarly, high 
expression of Dicer (HR, 0.32; 95% CI, 0.14-0.72; p=0.006) but not of Drosha (HR, 
0.93; 95% CI, 0.45-1.92; p=0.84) was associated with increased disease-free survival 
as well as distant recurrence–free survival and overall survival (data not shown) in the 
breast cancer cohort.  The relationship between high Dicer expression and increased 
disease-free survival was also observed in two other cohorts of breast cancer patients 
(HR, 0.33; 95% CI, 0.17-0.66; p=0.002; n=159; Figure 2E)13 and (HR, 0.64; 95% CI, 
0.42-0.97; p=0.036; n=249; Figure 2F)14. 
 
Mutational analysis of Dicer and Drosha in ovarian cell lines. We next asked whether 
the variable Dicer and Drosha expression could be explained by gene mutations.  
Genomic DNA from cell lines with low (HeyA8 and SKOV3ip1) and high (OVCAR3 and 
A2780-PAR) Dicer and Drosha were analyzed for mutations.  Two synonymous single-
nucleotide polymorphisms were discovered in both Dicer and Drosha sequencing in all 
four cell lines.  Two different non-synonymous mutations were noted in Drosha in 
OVCAR3 and A2780-PAR cell lines.  A splice-site mutation was discovered for Drosha 
in the SKOV3ip1 cell line.  RT-PCR failed to demonstrate truncation of Drosha in any of 
the four cell lines examined by mutational analysis (data not shown). 
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Comparison of in vitro gene silencing using shRNA or siRNA. Although low Dicer levels 
were associated with poor clinical outcomes in ovarian cancer patients, the functional 
relevance of this relative expression is not known.  Therefore, we compared the efficacy 
of silencing a constitutively expressed gene, Galectin-3, in ovarian cancer cell lines that 
were characterized by either high or low Dicer using either siRNA or shRNA 
transfections (Figure 3).  Compared to controls, siRNA reduced (78% and 95%) 
Galectin-3 levels in the HeyA8 and SKOV3ip1 (low Dicer) cells, respectively.  In 
contrast, very poor silencing was noted in these cells with shRNA (8% and 4%, 
respectively).  In the OVCAR3 and 222 cells (high Dicer), 62% to 73% Galectin-3 
silencing was observed with both siRNA and shRNA constructs.   
 
Discussion 
In this study, we found that Dicer and Drosha expression ratios vary significantly in 
ovarian cancer cell lines, as well as, invasive epithelial ovarian cancers and are 
significantly associated with patient survival.  The association is robust, being externally 
validated in independent ovarian, lung and breast cancer patients’ data sets.  While the 
precise mechanism for this association is incomplete, our transfection data suggests 
expression of these key processing enzymes are relevant to the looming field of RNAi-
based therapeutics.  
 
The production of mature endogenous interfering RNA involves a cascade of events 
inextricably linked to Dicer and Drosha function.  In cell culture models, silencing of 
Dicer and Drosha expression significantly reduces the production of precursor and 
 13
mature miRNAs5.  Loss of Dicer in mice is lethal during early development and disrupts 
embryonic stem cell differentiation20.  Further, DNA copy–number abnormalities of Dicer 
and Argonaute 2 (a component of RISC) have been described in human melanoma, 
breast, and ovarian cancers21.  It is therefore plausible, that dysregulated gene 
expression may result from functionally handicapped processing of endogenous 
silencing mechanisms in some tumors.  Our observation of differential Dicer and Drosha 
expression both in ovarian cancer cell lines and in human tumors supports this 
contention.  Clinically, we suggest this finding is independently represented by ovarian 
cancer mortality.  Not limited to ovarian cancer, decreased Dicer mRNA expression has 
also been associated with decreased survival in patients with non-small–cell lung 
cancer22.  Of interest, Dicer expression appeared to be up-regulated in noninvasive 
precursor lesions relative to invasive lung adenocarcinoma.23   
 
Underscoring the complexity of the RNAi machinery are observations in other tumor 
types which contradict our findings. High Dicer and Drosha expression correlated with 
poor prognostic factors in patients with prostate and esophageal carcinoma.24, 25  
Furthermore, reduction of Drosha expression in esophageal cancer cell lines with siRNA 
significantly reduced cellular proliferation25.  Nevertheless, these findings suggest that 
alterations in RNAi machinery play a role in cancer pathogenesis.   
 
Despite growing evidence that Dicer and Drosha expression varies among tumor types, 
the regulation of these genes remains unclear.  Recently, Dicer mutations were reported 
in C. elegans26, and in humans, Chiosea and colleagues found deletions of the Dicer 
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locus in a fraction of precancerous and invasive lung adenocarcinomas23.  Our 
mutational analysis demonstated that alterations of genomic DNA from cancer cells 
likely do not account for the variability in Dicer and Drosha levels.  Although a splice-site 
mutation of Drosha was discovered, these findings were not consistent among cell lines 
examined and did not appear to affect translational processing.  However, in breast cell 
lines, two forms of Dicer exist based on alternative splicing mechanisms which appear 
to affect protein stability27.  In addition, DNA methylation of the Dicer gene was not 
present in a small subset of lung cancer specimens 22.  As the function of miRNAs in 
tumorigenesis becomes clearer, further studies will be needed to delineate the 
regulation and stability of the RNAi machinery. 
 
From a developmental therapeutics standpoint, our discovery of the heterogeneous 
expression profile of Dicer and Drosha in ovarian cancer patients may have specific 
implications in constructing efficacious RNAi-based treatment.  To highlight this point, 
we demonstrated differential targeting efficiency of a constitutively expressed gene by 
two strategies of gene silencing; one dependent (shRNA) and one independent (siRNA) 
of Dicer processing. In the presence of functional Dicer, both strategies silenced 
Galectin-3 expression; however, only siRNA was efficacious in the cell lines without 
Dicer.  Nevertheless, shRNA-based therapy has been explored in several in vivo 
models as the imperfect complimentarity to the target gene has the potential to induce 
robust gene silencing for cancer therapy.  However, in one study, Grimm and 
colleagues reported increased mortality in mice after delivery of multiple shRNA 
sequences, which was thought to be related to competition between exogenous shRNA 
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and the production and expression of host miRNAs, thereby overwhelming key 
components of the RNAi cascade28.  We previously demonstrated that siRNA-mediated 
therapy was highly effective in decreasing tumor growth and angiogenesis with no 
apparent evidence of drug-related toxicity in preclinical mouse cancer models2, 16.  
Since low Dicer characterizes a relevant proportion of ovarian cancers, RNAi-based 
therapy will have to consider altered integrity of these processing enzymes. 
 
 
In conclusion, Dicer and Drosha expression was associated with clinical outcome in 
ovarian carcinoma.  As investigators begin to define the role of interfering RNAs in 
humans, these findings could directly relate to any protective role that miRNAs may play 
in tumor development and progression.  Nevertheless, given the substantial proportion 
of tumors with low expression of Dicer, siRNA-based therapeutic approaches may be 
more attractive than RNAi fragments that require Dicer function. 
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Figure Legends 
 
Figure 1.  Dicer and Drosha expression in ovarian cell lines. A) Real-time PCR analysis 
of Dicer and Drosha mRNA expression in a non-transformed ovarian epithelial cell line 
(HIO-180) and invasive ovarian epithelial cancer cell lines. 2-ΔΔCT= Ratio of Dicer and 
Drosha expression relative to that in the HIO-180 cell line 18. B) Western blot analysis of 
Dicer and Drosha. C) Densitometry analysis.  
 
Figure 2.  Kaplan-Meier survival curves of patients with invasive epithelial ovarian 
cancer in relation to tumor expression of A) Drosha and Dicer, B) Dicer and Drosha 
combined relative to that in benign ovarian epithelium.  Kaplan-Meier survival curves of 
validation analyses for Dicer and/or Drosha expression in independent ovarian (C), lung 
(D), and breast (E-F) patient cohorts.  
 
Figure 3.  Comparison of siRNA and shRNA transfections targeting Galectin-3 in 
ovarian cancer cell lines with low Dicer (HeyA8 and SKOV3ip1) and high Dicer 
(OVCAR3 and 222) expression levels by Western blotting.  Densitometry analysis 
comparing Galectin-3 silencing (normalized to actin loading) to control transfections with 
non-targeting sequences. 
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N (%)
(N=111)
Individual Low Dicer 66 (59.5)
Low Drosha 57 (51.4)
Joint Low Dicer and Drosha 43 (38.7)
High Dicer, Low Drosha 14 (12.6)
Low Dicer, High Drosha 23 (20.7)
High Dicer and Drosha 31 (27.9)
Supplementary Table 1. Distribution of Dicer and 
Drosha expression in ovarian cancer tumors
Variable N (%)
N=111
Age* 62.5 (25-96)
Stage I/II 8 (7.2)
III/IV 103 (92.8)
Cytoreduction Optimal 86 (77.5)
Suboptimal 25 (22.5)
Grade Low (1 or 2) 16 (14.4)
High (3) 95 (85.6)
Response to initial 
chemotherpay
Sensitive 59 (53.2)
Resistant/ Refractory 37 (33.3)
Missing 15 (13.5)
Status Alive with disease 14 (12.6)
Alive without disease 33 (29.7)
Dead of disease 64 (57.7)
*Mean (Range)
Table 1. Demographic features of patients with invasive 
ovarian cancer
Drosha Dicer
Variable Low 
N (%)
High 
N (%)
p value Low 
N (%)
High 
N (%)
p value
Age Mean (SD) 61.2 (12.95) 63.8 (11.66) 0.37 63.1 (11.70) 61.6 (13.34) 0.74
Stage I & II 2 (3.5) 6 (11.1) 0.15 1 (1.5) 7 (15.6) <0.01
III & IV 55 (96.5) 48 (88.9) 65 (98.5) 38 (84.4)
Grade Low 7 (12.3) 9 (16.7) 0.59 9 (13.6) 7 (15.6) 0.79
High 50 (87.7) 45 (83.3) 57 (86.4) 38 (84.4)
Cytoreduction Optimal 39 (68.4) 47 (87.0) 0.02 47 (71.2) 39 (86.7) 0.07
Suboptimal 18 (31.6) 7 (13.0) 19 (28.8) 6 (13.3)
Response to initial 
chemotherpay
Sensitive 27 (47.4) 32 (59.3) 0.35 31 (47.0) 28 (62.2) 0.15
Resistant/
Refractory
20 (35.1) 17 (31.4) 23 (34.8) 14 (31.1)
Missing 10 (17.5) 5 (9.3) 12 (18.2) 3 (6.7)
Table 2.  Correlation of clinical and pathological features with Dicer and Drosha expression in 
invasive epithelial ovarian carcinoma


